09:58 AM EST, 02/27/2025 (MT Newswires) -- Teleflex ( TFX ) said Thursday it has agreed to acquire most of Biotronik's Vascular Intervention business for about 760 million euros ($793.1 million) in cash, with the deal expected to close by the end of Q3.

The company said the acquisition will add coronary and peripheral vascular intervention devices to its portfolio.

The business generated a 5.4% constant currency revenue compound annual growth rate from 2022 to 2024 and is expected to contribute about 91 million euros in revenue in Q4 of 2025, Teleflex ( TFX ) said.

Teleflex ( TFX ) said it expects the purchase to add about $0.10 to adjusted earnings per share in the first year post-close.

Teleflex ( TFX ) said it will finance the acquisition through a new term loan, revolving credit, and cash on hand.

Teleflex ( TFX ) shares were more than 20% lower in recent trading.

Price: 150.73, Change: -26.90, Percent Change: -15.14